Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

European Regulators Reject Pfizer Inc's Arthritis Drug-Reuters


Friday, 26 Apr 2013 05:02pm EDT 

Reuters reported that European regulators declined to approve marketing of Pfizer Inc's new rheumatoid arthritis treatment Xeljanz, citing the risks of the drug compared with its potential benefit, the Company said on April 25, 2013. Pfizer said it plans to appeal and 'immediately seek a re-examination of the opinion' by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). 

Company Quote

6.59
-0.21 -3.09%
19 Dec 2014